Article Text

Download PDFPDF
HPV vaccine: positive insights from universal adolescent HepB vaccination
  1. J Claire Cameron1,
  2. Lesley A Wallace1,
  3. Syed Ahmed2,
  4. Rina Duff3,
  5. Martin Donaghy1,
  6. David J Goldberg1
  1. 1
    Health Protection Scotland, Glasgow, UK
  2. 2
    NHS Greater Glasgow and Clyde, Glasgow, UK
  3. 3
    East Renfrewshire Community Health Care Partnership, Glasgow, UK
  1. Dr J Claire Cameron, Epidemiologist (Immunisation), Health Protection Scotland, Clifton House, Clifton Place, Glasgow G3 7LN, UK; claire.cameron{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The introduction of universal adolescent HPV vaccination in schools has a positive outlook

Preventing cervical cancer by vaccination has become a reality, complementing highly successful screening programmes. One vaccine against human papillomavirus (HPV) is already licensed (Gardasil®, Sanofi Pasteur), and approval for a second (Cervarix®, GSK) is expected shortly. Trials indicate over 90% efficacy in preventing persistent infection with vaccine types (HPV-16 and 18).1 2 In several countries, including the United States, Canada, Australia, Austria, Italy, Germany and France, HPV vaccination has now been universally recommended. Other countries, including the UK, are considering recommendations for its use.

The clinical benefit of HPV vaccines is incontrovertible, and excellent safety profiles have been established. As HPV is a sexually transmitted infection, however, some groups are anxious that vaccination may encourage earlier sexual activity.3 Further, uncertainty about the programme’s optimal delivery setting remains.3

However, precedents exist. First, with rubella, against which many countries vaccinated adolescent schoolgirls to protect during later pregnancy, and more recently with hepatitis B (HepB), against which some countries, including Italy, Spain and France, have had universal …

View Full Text


  • Competing interests: Health Protection Scotland and NHS Greater Glasgow and Clyde have received funding for research and conference attendance from pharmaceutical companies.

  • Abbreviations:
    human papillomavirus

Linked Articles

  • In this issue
    Carlos Alvarez-Dardet John Ashton